Sachs David C. 4
4 · ImmunityBio, Inc. · Filed Feb 24, 2026
Insider Transaction Report
Form 4
Sachs David C.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-22+40,650→ 320,825 total - Tax Payment
Common Stock
[F2]2026-02-22$8.70/sh−20,682$179,933→ 300,143 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-02-22−40,650→ 40,651 total→ Common Stock (40,650 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
- [F2]On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.
- [F3]Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
Signature
/s/ Philip LoScalzo, as Attorney-in-Fact|2026-02-24